These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 36103562)

  • 1. Neurofilament light chain in blood as a diagnostic and predictive biomarker for multiple sclerosis: A systematic review and meta-analysis.
    Ning L; Wang B
    PLoS One; 2022; 17(9):e0274565. PubMed ID: 36103562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cerebrospinal fluid neurofilament light chain in multiple sclerosis and its subtypes: a meta-analysis of case-control studies.
    Martin SJ; McGlasson S; Hunt D; Overell J
    J Neurol Neurosurg Psychiatry; 2019 Sep; 90(9):1059-1067. PubMed ID: 31123141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glial and neuroaxonal biomarkers in a multiple sclerosis (MS) cohort.
    Kalatha T; Hatzifilippou E; Arnaoutoglou M; Balogiannis S; Koutsouraki E
    Hell J Nucl Med; 2019; 22 Suppl 2():113-121. PubMed ID: 31802051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of cerebrospinal fluid neurofilament light chain and chitinase-3-like-1 in newly diagnosed patients with multiple sclerosis.
    Sellebjerg F; Royen L; Soelberg Sørensen P; Oturai AB; Jensen PEH
    Mult Scler; 2019 Oct; 25(11):1444-1451. PubMed ID: 30113249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cerebrospinal fluid neurofilament light chains and CXCL13 as predictive factors for clinical course of multiple sclerosis.
    Hradilek P; Revendova KZ; Horakova J; Bunganic R; Pelisek O; Zeman D; Hanzlikova P; Kusnierova P
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2023 Mar; 167(1):30-35. PubMed ID: 36695545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of Chitinase 3-like 1 as a Biomarker in Multiple Sclerosis: A Systematic Review and Meta-analysis.
    Floro S; Carandini T; Pietroboni AM; De Riz MA; Scarpini E; Galimberti D
    Neurol Neuroimmunol Neuroinflamm; 2022 Jul; 9(4):. PubMed ID: 35534236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis.
    Martínez MA; Olsson B; Bau L; Matas E; Cobo Calvo Á; Andreasson U; Blennow K; Romero-Pinel L; Martínez-Yélamos S; Zetterberg H
    Mult Scler; 2015 Apr; 21(5):550-61. PubMed ID: 25732842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring CSF neurofilament light as a biomarker for MS in clinical practice; a retrospective registry-based study.
    Rosenstein I; Axelsson M; Novakova L; Blennow K; Zetterberg H; Lycke J
    Mult Scler; 2022 May; 28(6):872-884. PubMed ID: 34392718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuronal and glial CSF biomarkers in multiple sclerosis: a systematic review and meta-analysis.
    Momtazmanesh S; Shobeiri P; Saghazadeh A; Teunissen CE; Burman J; Szalardy L; Klivenyi P; Bartos A; Fernandes A; Rezaei N
    Rev Neurosci; 2021 Aug; 32(6):573-595. PubMed ID: 33594840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A candidate biomarker of glial fibrillary acidic protein in CSF and blood in differentiating multiple sclerosis and its subtypes: A systematic review and meta-analysis.
    Sun M; Liu N; Xie Q; Li X; Sun J; Wang H; Wang M
    Mult Scler Relat Disord; 2021 Jun; 51():102870. PubMed ID: 33819724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Score Based on NfL and Glial Markers May Differentiate Between Relapsing-Remitting and Progressive MS Course.
    Huss A; Otto M; Senel M; Ludolph AC; Abdelhak A; Tumani H
    Front Neurol; 2020; 11():608. PubMed ID: 32765393
    [No Abstract]   [Full Text] [Related]  

  • 12. Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials.
    Bar-Or A; Thanei GA; Harp C; Bernasconi C; Bonati U; Cross AH; Fischer S; Gaetano L; Hauser SL; Hendricks R; Kappos L; Kuhle J; Leppert D; Model F; Sauter A; Koendgen H; Jia X; Herman AE
    EBioMedicine; 2023 Jul; 93():104662. PubMed ID: 37354600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High neurofilament levels are associated with clinically definite multiple sclerosis in children and adults with clinically isolated syndrome.
    van der Vuurst de Vries RM; Wong YYM; Mescheriakova JY; van Pelt ED; Runia TF; Jafari N; Siepman TA; Melief MJ; Wierenga-Wolf AF; van Luijn MM; Samijn JP; Neuteboom RF; Hintzen RQ
    Mult Scler; 2019 Jun; 25(7):958-967. PubMed ID: 29774770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term prognostic value of longitudinal measurements of blood neurofilament levels.
    Häring DA; Kropshofer H; Kappos L; Cohen JA; Shah A; Meinert R; Leppert D; Tomic D; Kuhle J
    Neurol Neuroimmunol Neuroinflamm; 2020 Sep; 7(5):. PubMed ID: 32817406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined Cerebrospinal Fluid Neurofilament Light Chain Protein and Chitinase-3 Like-1 Levels in Defining Disease Course and Prognosis in Multiple Sclerosis.
    Gil-Perotin S; Castillo-Villalba J; Cubas-Nuñez L; Gasque R; Hervas D; Gomez-Mateu J; Alcala C; Perez-Miralles F; Gascon F; Dominguez JA; Casanova B
    Front Neurol; 2019; 10():1008. PubMed ID: 31608004
    [No Abstract]   [Full Text] [Related]  

  • 16. Cerebrospinal fluid neurofilament light chains predicts early disease-activity in Multiple Sclerosis.
    Toscano S; Oteri V; Chisari CG; Finocchiaro C; Lo Fermo S; Valentino P; Bertolotto A; Zappia M; Patti F
    Mult Scler Relat Disord; 2023 Dec; 80():105131. PubMed ID: 37951096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurofilament light levels are associated with long-term outcomes in multiple sclerosis.
    Kuhle J; Plavina T; Barro C; Disanto G; Sangurdekar D; Singh CM; de Moor C; Engle B; Kieseier BC; Fisher E; Kappos L; Rudick RA; Goyal J
    Mult Scler; 2020 Nov; 26(13):1691-1699. PubMed ID: 31680621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of neurofilament light chain in natalizumab therapy for different phases of multiple sclerosis: A systematic review and meta-analysis.
    Liu N; Sun M; Zhang W; Sun J; Gong P; Wang H; Wang M
    J Clin Neurosci; 2022 Jul; 101():198-203. PubMed ID: 35617924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparative study of CSF neurofilament light and heavy chain protein in MS.
    Kuhle J; Plattner K; Bestwick JP; Lindberg RL; Ramagopalan SV; Norgren N; Nissim A; Malaspina A; Leppert D; Giovannoni G; Kappos L
    Mult Scler; 2013 Oct; 19(12):1597-603. PubMed ID: 23529999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis.
    Axelsson M; Malmeström C; Nilsson S; Haghighi S; Rosengren L; Lycke J
    J Neurol; 2011 May; 258(5):882-8. PubMed ID: 21197541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.